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ABSTRACT
The formation of the cardiovasculature, consisting of both the heart
and blood vessels, is a critical step in embryonic development and
relies on three processes termed vasculogenesis, angiogenesis, and
vascular remodeling. The transmembrane protein NRP1 is an
essential modulator of embryonic angiogenesis with additional roles
in vessel remodeling and arteriogenesis. NRP1 also enhances
arteriogenesis in adults to alleviate pathological tissue ischemia.
However, in certain circumstances, vascular NRP1 signaling can be
detrimental, as it may promote cancer by enhancing tumor
angiogenesis or contribute to tissue edema by increasing vascular
permeability. Understanding the mechanisms of NRP1 signaling is,
therefore, of profound importance for the design of therapies
aiming to control vascular functions. Previous work has shown that
vascular NRP1 can variably serve as a receptor for two secreted
glycoproteins, the VEGF-A and SEMA3A, but it also has a poorly
understood role as an adhesion receptor. Here, we review current
knowledge of NRP1 function during blood vessel growth and
homeostasis, with special emphasis on the vascular roles of its
multiple ligands and signaling partners.
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INTRODUCTION
The cardiovascular system forms during embryonic devel-
opment to supply growing organs with oxygen and nutrients
via a hierarchical blood vessel network, with blood flow
generated by the pumping heart. Developmental blood vessel
growth occurs through the complementary processes of
vasculogenesis to form new vessels from single cell precursors
and angiogenesis to expand existing vessels by sprouting
growth or intussusception (reviewed in refs [16,64,65]).
These processes are accompanied by arteriovenous specifi-
cation to increase luminal caliber and allow the separation of
blood leaving the heart from blood that is returned to it. In
addition, endothelial cells acquire organ-specific properties.
Thus, endothelial cells in the glomerulus of the kidney
become fenestrated to allow passage of solutes, whereas
endothelial cells of the brain and retina establish tight
junctions to form blood barriers and maintain organ
homeostasis (reviewed in refs [64,67]). In most organs,
however, intermediate barrier properties are established
during embryonic development to enable appropriate serum
efflux and extravasation of circulating immune cells during
postnatal life.
After birth, angiogenesis continues to support growing
tissues, but most blood vessels become quiescent during
adulthood. The reactivation of quiescent vessels occurs only
under specific circumstances in adults, for example in the
cycling uterus and ovary, in the placenta during pregnancy,
and in skeletal muscle to support exercise-induced muscle
growth (reviewed in refs [16,41,42]). Angiogenesis is also
stimulated after injury to promote tissue repair through an
increased vascular supply, but this response can be detri-
mental, for example, in ocular pathologies such as prolifer-
ative diabetic retinopathy or the “wet” form of age-related
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macular degeneration, in which tissue ischemia leads to the
formation of ectopic and leaky blood vessels (reviewed in ref.
[16]). Moreover, tumor angiogenesis can promote tumor
growth, thus contributing to cancer progression. In such
diseases, neo-angiogenesis typically leads to the formation of
abnormal vessels with increased vascular permeability.
Although vascular permeability is beneficial after acute tissue
injury through the delivery of coagulation factors, antibodies,
and cytokines, chronic permeability can cause pathological
tissue edema.
In this review, we will describe current knowledge of
vascular signaling pathways mediated by the transmembrane
protein NRP1, a bifunctional receptor for the secreted
glycoproteins VEGF-A and SEMA3A that can additionally
promote cell-matrix interactions and adhesion (reviewed in
[26,71]). We will further discuss the relevance of these NRP1
pathways for the design of novel therapies aimed at
normalizing pathological vasculature and stimulating the
functional revascularization of ischemic organs.
DOMAIN STRUCTURE OF NRP1 AND ITS
HOMOLOG NRP2
NRP1 is a single-pass transmembrane glycoprotein of
130 kDa [26] that was originally discovered in the develop-
ing frog nervous system as an axonal adhesion protein [82]
and subsequently in mammals as a receptor for secreted axon
guidance cues of the class 3 semaphorin family such as
SEMA3A [38,49]. In addition to binding semaphorins, NRP1
also binds VEGF165, an isoform of the vascular endothelial
growth factor VEGF-A that arises through alternative
splicing [32,75]. These multiple NRP1 interactions are
facilitated by a large extracellular domain of 860 amino
acids that is organized into five domains, termed a1, a2, b1,
b2, and c (Figure 1A) [26,71]. Whereas the a and b domains
bind ligands, the c domain promotes oligomerization.
The class 3 semaphorins bind the a1 and a2 domains of
NRP1, and the disruption of this interaction leads to axonal
patterning defects without affecting vascular development
[36,87]. The b1 and b2 domains mediate binding to the
polysaccharide heparin sulfate and VEGF165, and they
additionally promote cell adhesion [35,55]; however, the
VEGF165 binding sites are distinct from the cell adhesion
sites [53,73]. More recently, structural studies of the b1
domain have identified key residues important for ligand
interactions in a VEGF165-binding pocket, such as tyrosine
(Y) 297 and aspartic acid (D) 320 [43,86,88]. In addition to
its extracellular domains, NRP1 has a short, 39 amino acid-
long intracellular/cytoplasmic tail that is thought to lack
catalytic activity (Figure 1A). However, the C-terminal SEA
motif in NRP1’s intracellular domain can recruit synectin, a
modulator of endocytic trafficking that is also known as
GIPC1 or NIP [4,8,17,28,51,69].
The neuropilin family also includes NRP2, which has
roughly 44% amino acid homology with NRP1 and an
identical domain structure [14]. NRP2 also binds VEGF-A
isoforms and class 3 semaphorins, with preferential binding of
VEGF145 and SEMA3F over VEGF165 and SEMA3A, respec-
tively [33]. Although semaphorin signaling through NRP2
plays an important role in neurons, NRP2 is dispensable for
blood vascular patterning in mice. NRP2 knockout mice do,
however, havemild lymphatic defects [97]. Thus, in contrast to
NRP2, NRP1 has pleiotropic and essential roles in the blood
vasculature and is, therefore, the focus of this review.
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Figure 1. NRP1-regulated signaling pathways in endothelial cells in vitro. (A) VEGF165 induces complex formation between NRP1 and VEGFR2 to enhance
VEGFR2 signaling in endothelial cells in vitro. In particular, biochemical studies suggested possible roles for NRP1 in the VEGF-mediated induction of pathways
involving the activation of ERK, AKT, SRC, P38 MAPK, and p130 CAS. (B) NRP1 regulates integrin-dependent fibronectin remodeling in primary arterial
endothelial cells and tumor cells in a mechanism that depends on the NRP1 cytoplasmic domain, but is thought to be VEGFR2 independent.
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NRP1 IN VASCULAR DEVELOPMENT
During development, NRP1 expression is prominent in
growing blood vessels, for example on the endothelial cells of
capillaries, arteries, and veins in the postnatal mouse retina
and in capillaries in the mouse embryo hindbrain on
embryonic day (E) 11.5 [21–23]. The importance of NRP1
for vascular growth was first demonstrated by NRP1
overexpression studies in the mouse embryo, which led to
the excessive growth of vessels that were leaky and hemor-
rhagic [48]. In contrast, loss of NRP1 function in mouse
embryos reduces vessel sprouting in organs vascularized by
angiogenesis, especially the brain and spinal cord, and it also
impairs the remodeling of the heart outflow tract, leading to
embryonic lethality by E12.5 in the CD1 mouse background
[24,31,47]. In the C57Bl/6 background, NRP1 loss addition-
ally impairs yolk sac vascularization and, therefore, causes
death at E10.5 [44], while the JF1 background is compatible
with survival up to E14.5 [9,70]. These observations suggest
the existence of important, but as yet unidentified genetic
modifiers for NRP1 signaling.
In zebrafish, two NRP1 homologs have been identified:
nrp1a, whose sequence is phylogenetically more similar to the
mammalian gene, and nrp1b, which originates from an early
duplication of the NRP1 gene during the evolution of teleost
fish [6,57,96]. Knockdown studies with morpholinos for
either gene reported impaired intersegmental vessel pattern-
ing and resulted in improper arteriovenous connections,
suggesting that both nrp1 genes are required for vascular
development in fish [52,57,90].
Several studies had raised the possibility that non-
endothelial NRP1 regulates angiogenesis. For example,
NRP1 is expressed on multiple cell types in an angiogenic
setting. Thus, NRP1 is expressed by the tumor cells as well as
the tumor vasculature (e.g., [76]), and in the endothelium
alongside neural progenitors and tissue macrophages during
hindbrain angiogenesis [24]. Moreover, the angiogenic brain
defects of endothelial NRP1 knockouts are milder than those
of full knockouts [24]. Using Cre-LoxP technology to create
cell type-specific NRP1 mutants in the hindbrain angiogen-
esis model, we recently examined the dependence of vascular
development on endothelial versus nonendothelial NRP1.
Surprisingly, we found that, NRP1 was required only on the
vascular endothelium for normal angiogenesis, despite its
abundant expression by nonendothelial cells [24]. Genetic
mosaic experiments further demonstrated that NRP1 is
required within the angiogenic endothelium to generate the
specialized tip cells that lead vessel sprouts [24].
NRP1 LIGANDS IN ANGIOGENESIS: VEGF165
Based on prior biochemical and tissue culture studies,
vascular NRP1 functions are widely thought to be mediated
by its binding to VEGF165, as this is the VEGF-A isoform
with the strongest affinity for NRP1. However, our genetic
mouse studies had raised the possibility that NRP1 can also
function in angiogenic endothelial cells in a VEGF-indepen-
dent manner. Most notably, mice expressing only VEGF120
at the expense of NRP1-binding VEGF (Vegfa120/120 mice)
display vascular defects that are different to those of full
NRP1 knockout mice; for example, the perisomitic vessels
branch normally in E10.5 Nrp1-null mutants, whereas their
branching is reduced in Vegfa120/120 mutants [68]. Further-
more, the vascular defects in the E12.5 hindbrain differ
qualitatively in both types of mutants: Although Nrp1-null
brains show a severe reduction in vessel branching specifi-
cally in the subventricular zone, with vessels terminating in
bulbous vascular tufts [24,31], Vegfa120/120 brains show a
milder reduction in vessel branching that is accompanied by
increased vascular diameter and impaired sprouting both
into and within the brain [23,68]. In fact, the vascular defects
of Vegfa120/120 mutants are better explained by the differential
affinity of VEGF-A isoforms for the extracellular matrix than
their distinct receptor binding properties. Thus, VEGF121 is
highly and VEGF165 partly diffusible, whereas VEGF189 is
retained in the matrix, unless released by proteases [61].
These binding properties are thought to allow the isoforms to
form chemotactic gradients critical for normal vascular
morphogenesis [30,68].
To directly evaluate the importance of VEGF binding to
NRP1 for angiogenesis in vivo, we recently examined
Nrp1Y297A/Y297A mice expressing NRP1 with a point mutation
in the VEGF binding pocket [20], as the mutated residue was
previously shown to be important for high affinity VEGF
binding by NRP1 [40,43]. The Nrp1Y297A/Y297A mutants do
not show the severe embryonic vascular defects of full or
endothelial-specific NRP1 knockouts [20]. Hence, VEGF
binding to NRP1 is not essential for embryonic angiogenesis,
and, therefore, NRP1 must have VEGF-independent roles in
angiogenesis that likely synergize with its known role as a
VEGFR2 coreceptor.
Although VEGF binding to NRP1 appeared to be largely
dispensable for embryonic angiogenesis, the study of new-
born and adult Nrp1Y297A/Y297A mice revealed essential roles
for NRP1 in postnatal angiogenesis and arteriogenesis in the
heart and retina, and in pathological neovascularization in a
model of neonatal eye disease [20]. In these settings, the
vascular phenotypes of Nrp1Y297A/Y297A mutants closely
resemble the ones of Vegfa120/120 mice lacking NRP1-binding
VEGF, suggesting that NRP1-mediated VEGF-signaling is
more important for perinatal and pathological neo-
vascularization than embryonic vascular development. How-
ever, because the targeting strategy used to create the
Nrp1Y297A/Y297A mice inadvertently also reduced NRP1
expression, further studies will be required to unequivocally
define the specific contribution of VEGF165 signaling
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through NRP1 to both embryonic and postnatal angiogen-
esis, as well as pathological neovascularization.
NRP1 LIGANDS IN ANGIOGENESIS: SEMA3A
As mentioned above, the extracellular NRP1 domain has
distinct VEGF165 and semaphorin binding domains to
which these two ligands bind noncompetitively [3]. How-
ever, in vivo studies showed that neither SEMA3A nor
semaphorin signaling through NRP1 and NRP2 are essen-
tial for embryonic angiogenesis in the mouse [36,87].
Moreover, abolishing both SEMA3A and VEGF164 in mice
impairs brain vascularization no differently than loss of
VEGF164 alone [87]. These observations argue against an
obvious role for semaphorin signaling through NRP1 in the
vasculature of developing mice. In zebrafish, however,
decreasing the levels of either of two SEMA3A orthologs
impairs vascular development [74,84]. The exogenous
delivery of SEMA3A also disrupts VEGF-A-mediated
angiogenesis in the chick chorioallantoic membrane assay
[1]. It is not yet known why SEMA3A affects angiogenesis
in developing fish and chick, but is dispensable for
angiogenesis in mouse embryos. In addition, SEMA3A has
been reported to also affect pathological angiogenesis in
mice. For example, SEMA3A prevents vascular regeneration
in a mouse model of oxygen-induced retinopathy [45] and
inhibits tumor angiogenesis by eliciting endothelial cell
apoptosis and normalizing the pericyte coverage of tumor
vessels [12,54]. SEMA3A-induced tumor vessel normaliza-
tion might be indirectly caused by SEMA3A-mediated
recruitment of a subset of NRP1-expressing monocytes that
secrete several factors involved in vessel maturation [11,98].
NRP1 LIGANDS IN ANGIOGENESIS:
INTEGRIN LIGANDS IN THE EXTRACELLULAR
MATRIX
In agreement with the original discovery of NRP1 as an
adhesion molecule in the nervous system [82], NRP1 was
shown to promote endothelial cell attachment to extracel-
lular matrix [59] and to directly interact with integrins
in vitro (Figure 1B) [27,85]. Moreover, avb3 integrin can
negatively regulate VEGF-A-mediated angiogenesis by lim-
iting the interaction of NRP1 with VEGFR2 [66]. The
domains that enable NRP1 to modulate adhesion to
heterologous, but unidentified proteins on neighboring
cells reside in the b1 and b2 domains [73]. It is not yet
known whether NRP1-mediated intercellular or cell-matrix
adhesion regulates the interaction of blood vessels with
their environment during angiogenesis in vivo. Nevertheless,
NRP1-mediated extracellular matrix remodeling takes place
in primary arterial endothelial cells and tumor cells and
appears to be mediated by the NRP1 cytoplasmic tail
without requirement for VEGFR2 activation by VEGF
[85,95] (Figure 1B).
MECHANISM OF NRP1 SIGNAL
TRANSDUCTION IN THE VASCULATURE:
ASSOCIATION WITH VEGFR2
The cytoplasmic tail of NRP1 lacks any known catalytic
activity, suggesting that NRP1 transduces signals in the
vasculature through a coreceptor. This would be analogous
to how NRP1 conveys semaphorin signals in the nervous
system, where A-type plexins function as a NRP1-coreceptor
and signal transducer [60]. Candidates for NRP1 signal
transduction in endothelial cells are the VEGF-A receptor
tyrosine kinases VEGFR1 (FLT1) and VEGFR2 (KDR), as
both have been shown to interact with NRP1 in vitro, and
because NRP1 increases VEGFR2 phosphorylation
[25,34,77,93]. In fact, the most widely accepted model of
NRP1 function in angiogenesis postulates that it forms a
VEGF165-dependent complex with VEGFR2 to enhance the
activation of a wide variety of intracellular signal transduc-
tion pathways, including those that involve (ERK) 1 and 2
(MAPK1 and MAPK3), the serine/threonine protein kinase
AKT1, the avian sarcoma viral oncogene homolog SRC, p38
MAPK (MAPK14) and the P130 CRK-associated substrate
(CAS), also known as breast cancer anti-estrogen resistance 1
(BCAR1) (Figure 1A) [1,5,19,46,51,89].
The VEGF165-mediated interaction between NRP1 and
VEGFR2 may occur in cis, if both receptors are coexpressed
on the same endothelial cell, or in trans, if VEGFR2 is
expressed by an endothelial cell and NRP1 by an adjacent
endothelial or nonendothelial cell. Thus, it has been
proposed that endothelial VEGFR2 may interact with tumor
NRP1 in trans [76]. However, the significance of trans
interactions has not yet been established for tumor angio-
genesis, nor is it known if trans interactions take place
between endothelial and mural cells in the dorsal aorta
[62,94]. We have recently shown that a trans interaction
between nonendothelial NRP1 and vascular endothelium is
dispensable for angiogenesis in the developing brain, where
endothelial NRP1 alone is essential for normal vessel growth
[24,36]. Thus, the ablation of NRP1 from the neural
progenitors that secrete VEGF-A for vessel sprouting or
from the macrophages that promote vascular anastomosis
did not compromise brain angiogenesis [24] (see above).
Recent in vitro studies suggest that NRP1-VEGFR2 com-
plex formation requires the C-terminal SEA motif in the
NRP1 cytoplasmic tail and its intracellular binding partner
synectin [63]. This complex is thought to promote ligand-
dependent endocytosis of VEGFR2-NRP1 complexes in
cultured endothelial cells [69]. Overexpression studies with
VEGF receptors and fluorophore-linked RAB proteins in
porcine aortic endothelial cells, which lack endogenous
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VEGF receptor expression, further suggested that the
synectin-binding motif of NRP1 promotes sequential,
NRP1-mediated VEGFR2 recycling through specific subsets
of RAB-vesicles after VEGF165 stimulation [4]. The latter
study concluded that NRP1-mediated VEGFR2 recycling
controls signaling output from VEGF-A-activated VEGFR2
complexes [4].
Although NRP1-mediated VEGFR2 trafficking was ini-
tially hypothesized to promote angiogenesis (e.g., ref [4]), the
analysis of mice lacking the cytoplasmic tail of NRP1 showed
that this domain is dispensable for developmental angio-
genesis in the mouse [22], which involves blood vessel
sprouting, migration, and vascular anastomosis. In contrast,
the NRP1 cytoplasmic tail is essential for efficient arterio-
genesis, a process that involves luminal vessel growth [51].
Thus, loss of the NRP1 cytoplasmic tail impairs arterial
morphogenesis during development and in adult hindlimb
ischemia, similar to the loss of synectin [15], which serves as
an adaptor to link VEGFR2 to myosin VI motors for
endocytic trafficking into EEA1+ endosomes [50]. Mecha-
nistically, these studies suggest a model in which the
cytoplasmic tail of NRP1 mediates VEGF165-stimulated
VEGFR2 cotrafficking with NRP1 via a synectin/myosin VI
complex into EEA1+ endosomes, where VEGFR2 is protected
from dephosphorylation by the phosphatase PTP1b to
maximize the phosphorylation of ERK1/2 [51], a previously
identified target of NRP1-dependent VEGFR2 signal trans-
duction (Figure 1A) [5].
VEGFR2-INDEPENDENT NRP1 SIGNALING IN
ENDOTHELIAL CELLS
Several tissue culture studies raised the possibility that NRP1
can promote endothelial migration and extracellular matrix
remodeling independently of VEGFR2. First, fusion of the
extracellular domain of the EGF receptor to the transmem-
brane and cytoplasmic domains of NRP1 creates a chimeric
receptor that promotes endothelial cell migration in response
to EGF, independently of VEGFR2 [91]. Second, NRP1 is
required for the VEGF-induced migration of primary
venous endothelial cells via activation of p130CAS, and
overexpression studies raise the possibility that this may
occur independently of VEGFR2 phosphorylation [19].
Third, NRP1 promotes adhesion of endothelial cells to low
concentrations of extracellular matrix component and inte-
grin ligand fibronectin, independently of VEGFR2 [59] in a
mechanism that involves the NRP1 cytoplasmic tail [85].
Because the cytoplasmic domain of NRP1 is dispensable for
developmental angiogenesis [22], these tissue culture studies
may have identified signaling pathways that are selectively
important for endothelial cell migration in specific circum-
stances, for example in pathological situations (although in
vivo evidence for this suggestion is still lacking). In contrast
to mice, zebrafish show defective vascular development in the
absence of the SEA motif in the NRP1 cytoplasmic domain
[90] or its interactor synectin [15]. These species differences
are reminiscent of the selective importance of SEMA3A for
zebrafish, but not mouse intersomitic vessel development
(see above). In summary, it is clear that NRP1 plays an
essential role in angiogenesis, but conflicting data obtained in
tissue culture, zebrafish, and mouse models need to be
resolved to fully understand the signaling mechanism of
NRP1 during angiogenesis and other vascular functions in
vivo.
ROLE FOR NRP1 IN ARTERIOVENOUS
PATTERNING
NRP2 is enriched in the venous and NRP1 in the arterial
parts of vascular networks in chick, mouse and zebrafish
[22,39,44,57]. Although Nrp2-null mice develop to term
without obvious arteriovenous or other type of blood
vascular defects [97], specific arterial markers are missing
from arterioles and arteries in full and endothelial-specific
Nrp1 knockouts [44,58]. The arterial differentiation defects
observed in limb skin are thought to be due to defective
VEGF-A signaling [58]. In agreement, both the loss of NRP1
binding VEGF-A isoforms and, inversely, the loss of VEGF-A
binding to NRP1 impair arterial development in the retina
and the heart in a similar manner [10,80]. Endothelial NRP1
deficiency also precludes normal remodeling of the arterial
pole of the developing heart from a common outflow tract
into the pulmonary artery and aorta [36]. This observation
has been proposed to be due to defective VEGF-A binding to
NRP1 on outflow tract endothelium [36], agreeing with the
observation that Vegfa120/120 mice lacking NRP1-binding
VEGF165 have similar defects [79]. However, loss of VEGF-A
binding to NRP1 does not affect embryonic viability, which
depends on a properly remodeled outflow tract [20], and
mice lacking semaphorin signaling through NRP1 also have
defective outflow tract remodeling [36]. Accordingly, further
work is needed to define the specific roles of NRP1 in
endothelial cells and other cell types that interact with the
endothelium during outflow tract remodeling, such as neural
crest cells.
Despite its essential role in arterial morphogenesis, the
NRP1 cytoplasmic domain is dispensable for NRP1-mediated
arterial differentiation in the retina; instead, the NRP1
cytoplasmic domain promotes the spatial segregation of
arteries and veins to regulate arteriovenous patterning in this
tissue. Specifically, retinal arteries and veins cross over each
other in the Nrp1cytoD/D mutants at an abnormally high
frequency [22]. In humans, similar arteriovenous crossings,
in the presence of additional systemic factors, are thought to
increase the likelihood of developing branch retinal vein
occlusion, in which compression of the vein by the artery
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disrupts retinal blood flow [7,92]. Arteriovenous crossings
have also been identified in the retina of mice with
haploinsufficient expression of VEGF-A in neural progeni-
tors [37], suggesting that NRP1 conveys VEGF-A signals
through its cytoplasmic domain to implement the spatial
separation of arteries and veins in the retina. However, is not
yet known if this process requires NRP1 expression in
endothelial or mural cells, as the latter are also known to
express NRP1 in certain situations [62,94].
NRP1 IN VASCULAR PERMEABILITY
Although VEGF-A is best known as an angiogenic growth
factor, it was first described as a vascular permeability factor,
because it disrupts endothelial barrier function in tumors
and increases the leakage of serum proteins and therefore
interstitial pressure [72]. In an inflammatory setting, the
effect of VEGF-A on permeability is beneficial, because it
enables the delivery of clotting factors and antibodies, but in
chronic conditions such as age-related macular degeneration
it is detrimental, because tissue swelling impairs vision.
Mechanistically, VEGF-A-mediated VEGFR2 activation
induces the internalization of VE-cadherin from adherens
junctions [18] and increases paracellular permeability in a
SRC- and T-cell-specific adapter (TSAD) (SH2D2A)-depen-
dent mechanism [29,81]. Supporting an additional role of
NRP1 in VEGF-mediated vascular permeability, mice that
overexpress soluble NRP1 in the skin show reduced leakage
in response to VEGF165 in the Miles assay, a technique that
measures vascular leak in the skin [56]. Moreover, antibody
neutralization of NRP1 attenuates VEGF165-induced vascu-
lar leakage in lung tissue [5]. Interestingly, C-end rule
peptides with a C-terminal arginine residue in a configura-
tion similar to that of VEGF-A bind NRP1 to induce vascular
permeability [83], and this property may be exploited to
enhance tumor penetration of chemotherapeutic drugs [2].
It is not yet clear how NRP1 and VEGFR2 cooperate to
regulate vascular permeability. On the one hand, NRP1 and
VEGFR2 need to be coexpressed in porcine aortic endothelial
cells to restore the VEGF165-induced decrease in transen-
dothelial electrical resistance, an inverse indicator of perme-
ability [5]. On the other hand, some experiments suggest that
NRP1 promotes permeability independently of VEGFR2.
First, blocking VEGFR2 in pulmonary artery endothelial cells
does not prevent the VEGF165-mediated decrease in
transendothelial electrical resistance, while blocking NRP1
does [5]. Second, a mutant form of VEGF165 lacking the
ability to bind VEGFR2, but predicted to still bind NRP1, can
also induce vascular permeability [78].
In addition to binding VEGF165, NRP1 can also bind
SEMA3A to induce permeability in the Miles assay that
measures vascular permeability in the skin [1]. In agreement,
a recent study revealed that SEMA3A is induced in the neural
retina of diabetic humans and mice, where it promotes
vascular leakage in a NRP1-dependent way [13]. SEMA3A
binding to NRP1 may, therefore, provide a therapeutic target
in diabetic retinopathy. It has not yet been investigated if this
pathway is also involved in other diseases in which elevated
vascular permeability is a contributing factor, such as cancer,
stroke, and other eye diseases. Moreover, further studies are
required to better discern the precise downstream mecha-
nisms that enable the VEGF-A isoforms and semaphorins to
regulate vascular permeability in vivo.
PERSPECTIVE
Due to its pleiotropic roles in angiogenesis, arteriogenesis,
and vascular permeability, NRP1 provides a promising
molecular target for diseases involving aberrant vascular
growth or excessive vascular leak. In particular, a better
understanding of NRP1 signaling may enable the design of
therapies that can revascularize ischemic tissues via VEGF-A-
stimulated angiogenesis and arteriogenesis, but avoid induc-
tion of excess vascular leak.
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